Nature Medicine, Published online: 09 November 2026; doi:10.1038/s41591-026-04741-8
An analysis of patient-reported trajectories of response to vedolizumab in ulcerative colitis defines disease endotypes and identifies vascular inflammation as a potential resistance mechanism.
